Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Non Operating Income (2016 - 2026)

Heron Therapeutics filings provide 11 years of Non Operating Income readings, the most recent being -$3.3 million for Q1 2026.

  • On a quarterly basis, Non Operating Income fell 544.7% to -$3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.5 million, a 13.84% increase, with the full-year FY2025 number at $1.3 million, up 211.4% from a year prior.
  • Non Operating Income hit -$3.3 million in Q1 2026 for Heron Therapeutics, down from $4.7 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $4.7 million in Q4 2025 to a low of -$6.9 million in Q2 2022.
  • Median Non Operating Income over the past 5 years was -$234500.0 (2023), compared with a mean of -$471687.5.
  • Biggest five-year swings in Non Operating Income: plummeted 1156.59% in 2022 and later soared 455.25% in 2024.
  • Heron Therapeutics' Non Operating Income stood at $1.3 million in 2022, then tumbled by 105.98% to -$79000.0 in 2023, then skyrocketed by 2596.2% to $2.0 million in 2024, then surged by 136.56% to $4.7 million in 2025, then crashed by 171.73% to -$3.3 million in 2026.
  • The last three reported values for Non Operating Income were -$3.3 million (Q1 2026), $4.7 million (Q4 2025), and -$2.1 million (Q3 2025) per Business Quant data.